| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Sulfopin specifically targets Pin1 (peptidyl-prolyl isomerase NIMA-interacting 1), a key enzyme that catalyzes the cis-trans isomerization of proline residues and regulates the function of numerous phosphoproteins, including c-Myc. It covalently binds to the active site cysteine Cys113.
|
|---|---|
| ln Vitro |
The MDA-MB-468 cells responded to SuLfopin (1, 2.5 μM; 4–8 days) with the greatest body weight [1]. Myc is neatly packaged by SuLfopin (2 μM, HEK293 cells; 48 hours) [1]. 1, 2.5 μM; PATU-8988T cells; 4 days) revealed a commensurate rise in cells in the growth 1 (G1) phase and a minor but noteworthy reduction in the number of cells in the synthesis (S) phase [1].
Sulfopin demonstrates potent in vitro inhibition of Pin1 with a Ki of 17 nM in fluorescence polarization (FP) assays. Although it displays little to no cytotoxicity against a panel of 300 cancer cell lines, it has a significant impact on cancer cell growth after prolonged treatment. It induces downregulation of c-Myc target genes. |
| ln Vivo |
SuLfopin (40 mg/kg; po; QD/BID for 7 days) induces regression of neuroblastoma in mice [1]. SuLfopin (20-40 mg/kg; ip; daily for 27 days) induces regression of neuroblastoma in mice. SuLfopin (25-100 μM) induces neuroblastoma outbreak in zebrafish [1].
In vivo, Sulfopin reduces tumor progression and confers survival benefit in animal models. It suppresses MYCN-driven neuroblastoma initiation and the growth and survival of primary neuroblastoma tumor cell transplants in zebrafish. The compound blocks Myc-driven tumors in vivo and has demonstrated anticancer activity in preclinical models, particularly in MYC-driven tumors. |
| Enzyme Assay |
The enzymatic activity of Sulfopin against Pin1 is measured using fluorescence polarization (FP) assays. Recombinant Pin1 enzyme is incubated with a fluorescently labeled peptide substrate and varying concentrations of the compound. The change in fluorescence polarization upon substrate isomerization is monitored. Ki values are calculated from the inhibition curves.
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: Kuramochi, MDA-MB-468, NGP, NBL-S, MDA-MB-468 Cell Tested Concentrations: 1, 2.5 μM Incubation Duration: 4, 6, 8 days Experimental Results: Display of different cancer cells There were differences in the antiproliferative effects of the lines Kuramochi, MDA-MB-468, NGP and NBL-S, with the most pronounced sensitivity observed in MDA-MB-468 cells. Cellular assays for Sulfopin involve treating cancer cell lines (particularly those with MYC or MYCN amplification) with the compound for extended periods (up to several days). Cell viability is measured using MTT or CellTiter-Glo assays. Target engagement is confirmed by assessing Pin1 activity in cell lysates using FP-based activity assays. c-Myc target gene expression is measured by qRT-PCR or Western blotting. |
| Animal Protocol |
Animal/Disease Models: transgenic Th-MYCN mice [1]
Doses: 40 mg/kg Route of Administration: one time/day (QD). ) or twice (two times) daily (BID) for 7 days. Experimental Results: The average survival time of Sulfopin-treated QD mice was Dramatically increased by 10 days, while the average survival time of Sulfopin-treated BID mice was Dramatically increased by 28 days. In vivo studies of Sulfopin are conducted in mouse xenograft models of MYC-driven tumors and in zebrafish neuroblastoma models. The compound is administered via intraperitoneal (i.p.) injection or oral gavage. Tumor growth is monitored by caliper measurements. Survival analysis is performed. Target engagement is confirmed by analyzing Pin1 activity and c-Myc target gene expression in tumor tissues. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Sulfopin are evaluated in rodents following administration. As a covalent inhibitor, its binding kinetics (k_inact/Ki) may be more relevant than conventional PK parameters. The compound's ability to achieve efficient cellular and in vivo target engagement has been validated by two independent chemical proteomic approaches.
|
| Toxicity/Toxicokinetics |
Standard toxicology assessments for Sulfopin would include acute and repeat-dose toxicity studies in rodents. The compound is intended for research use only and is not approved for clinical use. No specific toxicity data is available in the public domain. Its covalent binding mechanism warrants careful evaluation of potential off-target reactivity.
|
| References | |
| Additional Infomation |
Sulfonamides are sulfone compounds whose thiacyclopentane molecule is substituted with two carbonyl groups at position 1 and with a (chloroacetyl)(2,2-dimethylpropyl)amino group at position 3. It is a covalent inhibitor of Pin1 (Ki = 17 nM) and can inhibit Myc-driven tumors in vivo. It is an EC 5.2. (cis-trans isomerase) inhibitor and an antitumor drug. Sulfonamides belong to the tetrahydrothiophene class, sulfone class, organochlorine class, and tertiary amide class.
Sulfopin is a research tool for studying Pin1 biology and the therapeutic potential of Pin1 inhibition in cancer. Pin1 is a key regulator of oncogenic signaling pathways, including the c-Myc pathway. By covalently inhibiting Pin1, Sulfopin provides a means to validate Pin1 as a therapeutic target for MYC-driven cancers. It is a first-in-class covalent Pin1 inhibitor. |
| Molecular Formula |
C11H20CLNO3S
|
|---|---|
| Molecular Weight |
281.799401283264
|
| Exact Mass |
281.09
|
| Elemental Analysis |
C, 46.89; H, 7.15; Cl, 12.58; N, 4.97; O, 17.03; S, 11.38
|
| CAS # |
2451481-08-4
|
| PubChem CID |
155804394
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.6
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
17
|
| Complexity |
381
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NMHVAHHYKGXBMY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H20ClNO3S/c1-11(2,3)8-13(10(14)6-12)9-4-5-17(15,16)7-9/h9H,4-8H2,1-3H3
|
| Chemical Name |
2-chloro-N-(1,1-dioxidotetrahydrothiophen-3-yl)-N-neopentylacetamide
|
| Synonyms |
Sulfopin;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~354.86 mM)
H2O : ~4.35 mg/mL (~15.44 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5486 mL | 17.7431 mL | 35.4862 mL | |
| 5 mM | 0.7097 mL | 3.5486 mL | 7.0972 mL | |
| 10 mM | 0.3549 mL | 1.7743 mL | 3.5486 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
